NorthWest Biotherapeutics Inc (NWBO)

[Chiugray]

Sentiment, That is a smart, win-win pricing model for DCVax-L. Year 1 at under-$100K (mfg, 6 doses), year 2 at ~$40K(2 booster doses), and so on, until all doses are used up, not only sounds smart but sounds like:
- it communicates (to patients, hospitals, and insurance companies) the “immune durability” aspect
- that the subsequent payments are tied to "the curing” of the cancer
- and there is a potential continuing revenue model aspect to this.

So to say that is a win-win pricing model is probably an understatement.

Just to show contrast, consider that “2 previous meta-analyses demonstrated that novel cancer drugs only marginally extend life by 2 to 3 months on average.”
https://ascopubs.org/doi/full/10.1200/JCO.22.00535l
and that most novel new cancer drugs cost ~$200K per year, emphasize “each year”.

I also think there is a strategic marketing component built into this pricing model that is designed for market penetration.
- DCVax’s broad cancer vaccine benefits and tumor agnostic profile, give it a price elasticity advantage.
- Flaskworks gives it an economies of scale advantage.
- The cheaper it is, the more rapid the expansion DCVax will have into other cancer markets
- and as I see it, DCVax becomes a base-layer therapy for all cancers in the future.